MARKET

MEIP

MEIP

MEI Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.440
+0.100
+7.46%
Closed 16:00 03/30 EDT
OPEN
1.350
PREV CLOSE
1.340
HIGH
1.470
LOW
1.270
VOLUME
465.57K
TURNOVER
--
52 WEEK HIGH
3.410
52 WEEK LOW
0.7200
MARKET CAP
152.64M
P/E (TTM)
-2.8863
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of MEIP and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average MEIP stock price target is 8.67 with a high estimate of 11.00 and a low estimate of 6.00.

EPS

MEIP News

More
  • The Zacks Analyst Blog Highlights: Ensign, Gaia, MEI Pharma, Turning Point Brands and A10 Networks
  • Zacks · 3d ago
  • 5 Top Stocks That Have Skyrocketed in the Past 7 Days
  • Zacks · 4d ago
  • Those Who Purchased MEI Pharma (NASDAQ:MEIP) Shares Five Years Ago Have A 81% Loss To Show For It
  • Simply Wall St. · 03/13 14:04
  • The Zacks Analyst Blog Highlights: ResMed, Ensign, DaVita, KalVista Pharmaceuticals and MEI Pharma
  • Zacks · 02/18 14:46

Industry

Biotechnology & Medical Research
+4.00%
Pharmaceuticals & Medical Research
+4.75%

Hot Stocks

Symbol
Price
%Change

About MEIP

MEI Pharma, Inc. is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company's portfolio of clinical drug candidates includes Pracinostat, ME-344 and ME-401. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). ME-344 is an isoflavone-based mitochondrial inhibitor targeting a mitochondrial component of the terminal respiratory chain complex in rapidly proliferating cells. ME-401 is an oral inhibitor of phosphatidylinositide 3-kinase (PI3K) delta, a molecular target that plays a critical role in the proliferation and survival of hematologic cancer cells. Pracinostat has been tested in multiple Phase I and Phase II clinical trials in advanced hematologic malignancies and solid tumor indications.
More

Webull offers kinds of MEI Pharma Inc stock information, including NASDAQ:MEIP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MEIP stock news, and many more online research tools to help you make informed decisions.